Development and Validation of a Nomogram for Patients Undergoing Transarterial Chemoembolization for Recurrent Hepatocellular Carcinoma After Hepatectomy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62(4):1190–1200. doi:10.1002/hep.27969
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166. doi:10.1111/liv.12818
   PubMed Web of Science ®Google Scholar
• Park JW. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(4):583–705. doi:10.3350/cmh.2022.0294
   PubMed Web of Science ®Google Scholar
• Sangro B, Salem R. Transarterial chemoembolization and radioembolization. Semin Liver Disease. 2014;34(4):435–443. doi:10.1055/s-0034-1394142
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35–43. doi:10.1016/S1470-2045(08)70284-5
   PubMed Web of Science ®Google Scholar
• Yamakado K, Miyayama S, Hirota S, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol. 2014;32(5):260–265. doi:10.1007/s11604-014-0298-9
   PubMed Web of Science ®Google Scholar
• Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24(10):2565–2570. doi:10.1093/annonc/mdt247
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Arizumi T, Allara E, et al. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol. 2015;13(6):1204–8 e2. doi:10.1016/j.cgh.2014.11.037
   PubMed Web of Science ®Google Scholar
• Park Y, Kim SU, Kim BK, et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016;36(1):100–107. doi:10.1111/liv.12878
   PubMed Web of Science ®Google Scholar
• Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J Hepatol. 2019;70(5):893–903. doi:10.1016/j.jhep.2019.01.013
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• J-H L, Xie X-Y, Zhang L, et al. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3970–3977. doi:10.3748/wjg.v21.i13.3970
   PubMed Web of Science ®Google Scholar
• Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503–1510. doi:10.1016/0895-4356(95)00048-8
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J-FH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64(1):106–116. doi:10.1002/hep.28453
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Yamada T, Tanaka H, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg. 2006;244(5):771–780. doi:10.1097/01.sla.0000225126.56483.b3
   PubMed Web of Science ®Google Scholar
• Nomoto S, Hishida M, Inokawa Y, Sugimoto H, Kodera Y. Management of hepatocellular carcinoma should consider both tumor factors and background liver factors. Hepatobil Surg Nutr. 2014;3(2):82–85. doi:10.3978/j.issn.2304-3881.2014.02.13
   PubMedGoogle Scholar
• Zou Q, Li J, Wu D, et al. Nomograms for pre-operative and post-operative prediction of long-term survival of patients who underwent repeat hepatectomy for recurrent Hepatocellular carcinoma. Ann Surg Oncol. 2016;23(8):2618–2626. doi:10.1245/s10434-016-5136-0
   PubMed Web of Science ®Google Scholar
• Wang K, Liu G, Li J, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study. Eur J Surg Oncol. 2015;41(2):236–242. doi:10.1016/j.ejso.2014.11.002
   PubMed Web of Science ®Google Scholar
• Liu Y-W, Yong C-C, Lin -C-C, et al. Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival. Updates Surg. 2021;73(2):399–409. doi:10.1007/s13304-020-00931-2
   PubMed Web of Science ®Google Scholar
• Wei T, Zhang X-F, Bagante F, et al. Early versus late recurrence of hepatocellular carcinoma after surgical resection based on post-recurrence survival: an international multi-institutional analysis. J Gastrointest Surg. 2021;25(1):125–133. doi:10.1007/s11605-020-04553-2
   PubMed Web of Science ®Google Scholar
• Kuo M-J, L-R M, Chen C-L. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. BMC Cancer. 2021;21(1):250. doi:10.1186/s12885-021-07948-9
   PubMed Web of Science ®Google Scholar
• Ding X, He M, Chan AWH, et al. Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology. 2020. doi:10.1053/j.gastro.2019.09.056
   Google Scholar
• Xie D-Y, Fan H-K, Ren Z-G, Fan J, Gao Q. Identifying clonal origin of multifocal Hepatocellular carcinoma and its clinical implications. Clin Transl Gastroenterol. 2019;10(2):e00006. doi:10.14309/ctg.0000000000000006
   PubMedGoogle Scholar
• Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–207. doi:10.1016/S0168-8278(02)00360-4
   PubMed Web of Science ®Google Scholar
• Furuta M, Ueno M, Fujimoto A, et al. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. J Hepatol. 2017;66(2):363–373. doi:10.1016/j.jhep.2016.09.021
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul J-L, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a Phase III trial. J Hepatol. 2012;57(4):821–829. doi:10.1016/j.jhep.2012.06.014
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage Hepatocellular Carcinoma beyond up-to-seven criteria and Child-Pugh a liver function: a Proof-of-Concept Study. Cancers. 2019;11(8):1084. doi:10.3390/cancers11081084
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable Hepatocellular carcinoma. New Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Qin S, Ouyang X, Bai Y. Subgroup analysis of Chinese patients in a phase 3 study of lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. Hepatol Internat. 2019;2019(13):1. doi:10.1097/MD.0000000000000388
   Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379. doi:10.1200/JCO.2022.40.4_suppl.379
   Web of Science ®Google Scholar